Sionna director receives 17,340 stock options
Sionna Therapeutics director Paul J. Clancy received a new stock option award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sionna Therapeutics director Paul J. Clancy received a new stock option award. He was granted a non-qualified option for 17,340 shares of common stock at an exercise price of $36.73 per share, expiring on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics' next annual meeting, as long as he continues to serve through that vesting date. Following this grant, the filing shows Clancy holding 17,340 option shares directly.
Insider Trade Summary
Grant/Award: 17,340 shares
Grant/Award
1 txn
Insider
Clancy Paul J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 17,340 contracts (Direct)
Footnotes (1)
- F1. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Key Figures
Option shares granted: 17,340 shares
Exercise price: $36.73 per share
Expiration date: June 16, 2036
+2 more
5 metrics
Option shares granted
17,340 shares
Non-qualified stock option grant to director Paul J. Clancy
Exercise price
$36.73 per share
Exercise price of granted options
Expiration date
June 16, 2036
Option expiration for the grant
Vesting date trigger
June 17, 2027
Latest vesting date, or earlier next annual meeting
Post-transaction holdings
17,340 option shares
Total option shares held following grant
Key Terms
Non-Qualified Stock Option, exercise price, vesting, annual meeting
4 terms
Non-Qualified Stock Option financial
"He was granted a non-qualified option for 17,340 shares of common stock"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
exercise price financial
"at an exercise price of $36.73 per share, expiring on June 16, 2036"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics' next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting financial
"the earlier of June 17, 2027 or the date of Sionna Therapeutics' next annual meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sionna Therapeutics (SION) report for Paul J. Clancy?
Sionna Therapeutics reported that director Paul J. Clancy received a grant of non-qualified stock options for 17,340 shares. These options give him the right to purchase common stock at a fixed exercise price if the award eventually vests.
What is the exercise price of Paul J. Clancy’s Sionna Therapeutics (SION) stock options?
The granted non-qualified stock options have an exercise price of $36.73 per share. This means Clancy can buy Sionna Therapeutics common stock at $36.73 per share if and when the options vest and he chooses to exercise them.
When do Paul J. Clancy’s Sionna Therapeutics (SION) options vest?
The option award vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting. Vesting is conditioned on Clancy’s continued service with the company through that vesting date, according to the footnote.
When do Paul J. Clancy’s Sionna Therapeutics (SION) options expire?
The options expire on June 16, 2036, if not exercised earlier. After that expiration date, Clancy would no longer have the right to purchase Sionna Therapeutics common stock under this specific non-qualified stock option grant.
Was Paul J. Clancy’s Form 4 transaction in Sionna Therapeutics (SION) a market buy or sell?
The Form 4 shows a grant or award acquisition of derivative securities, not a market purchase or sale. Clancy received non-qualified stock options from Sionna Therapeutics as compensation, with no open-market buying or selling reported in this transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates